FY2028 Earnings Estimate for Insmed Issued By HC Wainwright

Insmed Incorporated (NASDAQ:INSM) – Equities research analysts at HC Wainwright raised their FY2028 EPS estimates for shares of Insmed in a note issued to investors on Wednesday, June 11th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will post earnings of $2.63 per share for the year, up from their previous estimate of $2.37. HC Wainwright currently has a “Buy” rating and a $120.00 target price on the stock. The consensus estimate for Insmed’s current full-year earnings is ($4.56) per share.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The firm had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Insmed’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.06) earnings per share.

A number of other research firms have also recently issued reports on INSM. Truist Financial upped their price objective on shares of Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Guggenheim reiterated a “buy” rating and set a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. Stifel Nicolaus lowered their price objective on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Friday, February 21st. UBS Group lowered their price objective on shares of Insmed from $110.00 to $109.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Insmed in a research report on Tuesday. One analyst has rated the stock with a sell rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.81.

Insmed Price Performance

INSM stock opened at $96.88 on Thursday. The company has a 50 day simple moving average of $70.73 and a 200 day simple moving average of $73.47. The stock has a market cap of $17.65 billion, a price-to-earnings ratio of -17.33 and a beta of 0.80. Insmed has a 1 year low of $60.40 and a 1 year high of $100.00. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insider Activity

In other news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the company’s stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total value of $9,264,648.24. Following the sale, the insider now directly owns 89,407 shares of the company’s stock, valued at approximately $8,352,401.94. This represents a 52.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Michael Alexander Smith sold 1,879 shares of the company’s stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $73.50, for a total transaction of $138,106.50. Following the completion of the sale, the insider now directly owns 67,718 shares in the company, valued at approximately $4,977,273. This represents a 2.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 262,166 shares of company stock valued at $20,585,587. 3.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. National Bank of Canada FI boosted its stake in Insmed by 9.7% during the fourth quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company’s stock worth $115,000 after acquiring an additional 147 shares in the last quarter. M&T Bank Corp boosted its stake in Insmed by 4.7% during the first quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company’s stock worth $252,000 after acquiring an additional 147 shares in the last quarter. Snowden Capital Advisors LLC boosted its stake in Insmed by 2.5% during the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company’s stock worth $456,000 after acquiring an additional 158 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its stake in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 163 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Insmed by 3.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,401 shares of the biopharmaceutical company’s stock worth $446,000 after acquiring an additional 186 shares in the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.